A detailed history of Amh Equity LTD transactions in Harvard Bioscience Inc stock. As of the latest transaction made, Amh Equity LTD holds 2,388,868 shares of HBIO stock, worth $5.11 Million. This represents 8.88% of its overall portfolio holdings.

Number of Shares
2,388,868
Previous 2,199,922 8.59%
Holding current value
$5.11 Million
Previous $6.27 Million 2.5%
% of portfolio
8.88%
Previous 8.75%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$2.64 - $3.54 $498,817 - $668,868
188,946 Added 8.59%
2,388,868 $6.43 Million
Q2 2024

Aug 06, 2024

SELL
$2.77 - $4.63 $344,250 - $575,407
-124,278 Reduced 5.35%
2,199,922 $6.27 Million
Q1 2024

May 06, 2024

BUY
$4.02 - $5.39 $648,454 - $869,444
161,307 Added 7.46%
2,324,200 $9.85 Million
Q4 2023

Feb 02, 2024

BUY
$4.0 - $5.49 $86,160 - $118,254
21,540 Added 1.01%
2,162,893 $11.6 Million
Q3 2023

Nov 06, 2023

BUY
$4.0 - $5.82 $565,412 - $822,674
141,353 Added 7.07%
2,141,353 $9.21 Million
Q2 2023

Aug 01, 2023

SELL
$4.19 - $6.16 $225,870 - $332,067
-53,907 Reduced 2.62%
2,000,000 $11 Million
Q1 2023

May 02, 2023

SELL
$2.45 - $4.22 $490,000 - $844,000
-200,000 Reduced 8.87%
2,053,907 $8.63 Million
Q4 2022

Jan 20, 2023

BUY
$2.12 - $2.86 $1.34 Million - $1.81 Million
633,124 Added 39.06%
2,253,907 $0
Q3 2022

Nov 03, 2022

BUY
$2.33 - $3.92 $863,924 - $1.45 Million
370,783 Added 29.66%
1,620,783 $4.15 Million
Q2 2022

Aug 01, 2022

BUY
$3.28 - $6.42 $1.55 Million - $3.04 Million
473,747 Added 61.03%
1,250,000 $0
Q1 2022

Apr 26, 2022

SELL
$5.16 - $7.14 $122,534 - $169,553
-23,747 Reduced 2.97%
776,253 $4.82 Million
Q4 2021

Jan 24, 2022

BUY
$6.37 - $8.18 $5.1 Million - $6.54 Million
800,000 New
800,000 $5.64 Million

Others Institutions Holding HBIO

About HARVARD BIOSCIENCE INC


  • Ticker HBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 41,636,500
  • Market Cap $89.1M
  • Description
  • Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as w...
More about HBIO
Track This Portfolio

Track Amh Equity LTD Portfolio

Follow Amh Equity LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amh Equity LTD, based on Form 13F filings with the SEC.

News

Stay updated on Amh Equity LTD with notifications on news.